Monopar Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Monopar Therapeutics

09/08/2024 14:31

* Monopar Therapeutics Inc  MNPR.OQ  reported a quarterly
adjusted
loss of 10 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -16 cents.  The mean expectation of
three analysts for the quarter was for a loss of 9 cents per
share. Wall Street expected results to range from -10 cents
to -8 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Monopar Therapeutics Inc's reported EPS for the quarter
was a
loss of 10 cents​.
    * The company reported a quarterly loss of $1.72 million.
    * Monopar Therapeutics Inc shares had fallen by 24.7% this
quarter and gained 61.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.8%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Monopar
Therapeutics Inc is $2.00 
This summary was machine generated from LSEG data August 9 at
01:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.09          -0.10          Missed
 Mar. 31 2024      -0.12          -0.10          Beat
 Dec. 31 2023      -0.15          -0.12          Beat
 Sep. 30 2023      -0.17          -0.14          Beat